New pill AC-003 tested for severe transplant complication

NCT ID NCT07070674

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called AC-003 in 24 adults who have acute graft-versus-host disease (aGVHD) after a stem cell transplant and whose condition has not improved with steroids. The study aims to see if the drug is safe and tolerable, and to get an early look at whether it might help control the disease. Participants will take AC-003 capsules by mouth, and researchers will monitor side effects and any signs of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AC-003 capsules
What this could lead to
If successful, this could point toward a new treatment option for patients with acute graft-versus-host disease that does not respond to steroids.
What could go wrong
This is a very early, small Phase Ib trial with only 24 participants, so results may not confirm safety or effectiveness. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)

    RECRUITING

    Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.